Document:

EX-10.18

 Exhibit 10.18 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

17 C.F.R. Section 200.80(b)(4) and Rule 406 of the 

Securities Act of 1933, as amended. 
  

 THIS AGREEMENT dated 23rd September, 2015 is made BETWEEN: 

 

	(1)	THE UNIVERSITY OF DUNDEE, established by Royal Charter dated 20 July 1967 and a registered Scottish charity (charity number SC015096) and having its principal office at 149 Nethergate, Dundee DD1 4HN
(“the University”); and 

  

	(2)	WAVE LIFE SCIENCES, PTE. LTD, a company registered under the laws of Singapore, with corporate offices at 419 Western Avenue, Boston MA 02135 (“the Sponsor”) 

 

	1.	DEFINITIONS 

 In this Agreement the following expressions have the meaning set opposite:

  

			
	Academic Publication:	  	the publication of an abstract, article or paper in a journal or an electronic repository; its presentation at a conference or seminar; or press release or other public announcement; and in clauses 5 and 6 “to Publish” and
“Publication” are to be construed accordingly;
		
	Affiliate	  	with respect to any Party, any other person or entity which directly or indirectly controls, is controlled by, or is under common control with, such Party. A person or entity, such as a corporation, partnership, limited liability
company, trust, business trust, association, joint venture, non-profit organization, or university shall be regarded as in control of another Party if it owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock or
other ownership interest of such Party, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of a Party by any means whatsoever.
		
	this Agreement:	  	this document, including its Schedules, as amended from time to time in accordance with clause 10.9;
		
	Background Information, Materials & IP:	  	(i) information, data, techniques, Know-how, software and Materials that are owned or controlled by a Party (regardless of the form or medium in which they are disclosed or stored) and that are provided by such Party to the other
for use in the Project during the Project Period, whether existing before or after the date of this Agreement and (ii) Intellectual Property that is owned or controlled by a Party prior to carrying out the Project or is conceived, developed or first
reduced to practice by a Party independently of the Project and provided by such Party for use in the Project during the Project Period.

  
 ***Confidential
Treatment Requested*** 

			
	a Business Day:	  	Monday to Friday (inclusive) except bank or public holidays in Scotland and the United States;
		
	Confidential Information:	  	any (i) Background Information, Materials & IP disclosed by a Party to the other for use in the Project and identified as confidential before or within [***] days of the time of disclosure; (ii) Research Reports; and (iii)
Results;
		
	the Effective Date:	  	1 September 2015
		
	the Financial Contribution:	  	the financial contribution to be provided by the Sponsor set out in Schedule 1;
		
	the Good Data Management Practices:	  	the practices and procedures set out in Schedule 3;
		
	Intellectual Property:	  	patents, trade marks, service marks, registered designs, copyrights, database rights, design rights, confidential information, trade secrets, applications for any of the above, and any similar right recognised from time to time in
any jurisdiction, or other rights issuing from, or filed subsequent to the date of this Agreement, based on or claiming priority to or from the applications, patents, and rights listed above, including but not limited to continuations, continuations
in part, divisionals, reexaminations, extensions, reissues, substitutions, renewals, supplementary protection certificates, registrations, and confirmations of any of the foregoing, and any patents resulting from any such application or right,
together with all rights of action in relation to the infringement of any of the above;
		
	Inventions	  	Any data or information, processes, compositions of matter, learnings, improvements and Know-how, whether or not patentable, conceived or reduced to practice by any Party in the course of performing the Project that may be used in
support of or as the basis or foundation for Intellectual Property.

  
 ***Confidential
Treatment Requested*** 

			
		
	the Key Personnel:	  	the Principal Investigator and any other key personnel identified in Schedule 2;
		
	Know-how	  	unpatented technical information including, without limitation, information relating to inventions, discoveries, concepts, methodologies, models, research, development and testing procedures, the results of experiments, tests and
trials, manufacturing processes, techniques and specifications, quality control data, prototypes, analyses, reports and submissions, trade secrets, in all cases whether or not patentable and that is not in the public domain, and specifically,
without limiting the foregoing: (i) data and information relating to the engineering, design or manufacture of stereo-controlled or stereo-pure nucleic acid based molecules; (ii) the general chemical stability, metabolism, pharmacokinetic or
pharmacodynamics effect of stereo-controlled or stereo-pure nucleic acid based molecules; and (iii) the use of stereo-controlled or stereo-pure nucleic acid based molecules to treat disease;
		
	the Location:	  	the location(s) at which the Project will be carried out as set out in Schedule 2;
		
	Materials	  	proprietary original material, progeny (every descendant from the Material), derivatives (a functional subunit of Material), any substance expressed by or from Material and modifications (substances created by the Recipient which
contain or incorporate Material or through use of Material), or any chemical compound derivatives, modifications and improvements, fragments or portion thereof and associated Know-how, information and data provided by the Sponsor to the University
under this Agreement and listed in Schedule 2 to this Agreement;
		
	Party	  	The Sponsor or the University are each referred to as a “Party” or collectively as the “Parties”;
		
	the Principal Investigator:	  	Dr Robyn Hickerson of the University or her successor appointed under clause 9.2;
		
	the Project:	  	the programme of work described in Schedule 2, as amended from time to time in accordance with clause 10.9;

  
 ***Confidential
Treatment Requested*** 

			
		
	the Project Period:	  	the period described in clause 2.1;
		
	the Results:	  	all (i) data, information, Know-how or Inventions first generated in the course of the Project, including underlying data, observations, theses, hypotheses and conclusions drawn therefrom and (ii) Intellectual Property conceived,
developed, identified or first reduced to practice or writing in the course of the Project;
		
	the Sponsor’s Supervisor:	  	Chandra Vargeese, Ph.D.

  

	2.	THE PROJECT 

  

	2.1	The Project will begin on the Effective Date and will continue until for a period of twenty-four (24) months or until any later date agreed in writing between the parties, or until this Agreement is terminated in
accordance with clause 8 or 9. 

  

	2.2	Each of the parties will carry out the tasks allotted to it in Schedule 2, and will provide the human resources, materials, facilities and equipment that are designated as its responsibility in Schedule 2. The Project
will be carried on under the direction and supervision of the Sponsor’s Supervisor. The Project will be carried out at the Location. 

  

	2.3	Each of the parties will use all reasonable endeavours to obtain all regulatory and ethical licences, consents and approvals necessary to allow it to carry out the tasks allotted to it in Schedule 2. 

 

	2.4	Each of the parties will ensure that its employees and students (if any) involved in the Project: (i) observe the conditions attaching to any regulatory and ethical licences, consents and approvals; (ii) keep
complete and accurate records of all research, development and other work carried out in connection with the Project and of all Results and observations, signed by the people who obtained each Result or made those observations, and countersigned by
an employee of that Party who is not a member of the research team but who understands the work; and (iii) comply with the Good Data Management Practices. 

  

	2.5	Although each of the parties will use reasonable endeavours to carry out the Project in accordance with Schedule 2, neither Party undertakes that any research will lead to any particular result, nor does it guarantee a
successful outcome to the Project. 

  

	2.6	 The University will keep the Sponsor advised of the progress of the Project and will provide the Sponsor with reports as it reasonably requests from
time to time, but on no less than a monthly basis. Such reports may be in email format and shall summarise the progress of the Project and detail the Results (each such report an “Interim Report”). Within [***] days following completion of
the Project, the University agrees to furnish the Sponsor with a formal written report setting forth all the Results generated in performing Project (“Final Report”). Such Interim Reports and the Final Report shall be collectively referred
to as the “Research Reports” and the Research Reports shall be Confidential Information under this Agreement. The 

  
 ***Confidential
Treatment Requested*** 

	 	
University shall use its reasonable efforts to ensure that the Research Reports include a clear, detailed and accurate description of the Results and include sufficient detail (when viewed
collectively) to adequately support patent applications relating to any Inventions. During the Project Period, the Principal Investigator and the Sponsor’s Supervisor and other representatives of the Parties as required will meet at times (but
no less than quarterly) and places mutually agreed upon, including by teleconference, with the purpose of reviewing the progress and Results, as well as ongoing plans, changes or amendments to the Project and identifying any Inventions arising from
the collaboration. 

  

	2.7	Each of the parties warrants to the other that it has full power and authority under its constitution, articles of association, by-laws, or other operating documents, and has taken all necessary actions and obtained all
authorisations, licences, consents and approvals, to allow it to enter into this Agreement. 

  

	3.	FINANCIAL CONTRIBUTION AND EXTERNAL FUNDING 

  

	3.1	The University will keep complete and accurate accounts of its expenditure on the Project. The Sponsor will pay the Financial Contribution to the University in accordance with Schedule 1 within [***] days after receipt
by the Sponsor of [***] invoices. Where the Financial Contribution is being claimed against costs and expenses incurred by the University, each invoice must be accompanied by a statement certified by an authorised officer of the University.

  

	3.2	All amounts payable to the University under this Agreement are exclusive of VAT (or any similar tax) which the Sponsor will pay at the rate from time to time prescribed by law. 

 

	3.3	If the Sponsor fails to make any payment due to the University under this Agreement, without prejudice to any other right or remedy available to the University, the University may charge interest (both before and after
any judgement) on the amount outstanding, on a daily basis at the rate of [***] per cent ([***]%) per annum above the London Interbank Offer Rate from time to time in force. That interest will be calculated from the date or last date for payment to
the actual date of payment, both dates inclusive, and will be compounded annually. The Sponsor will pay that interest to the University on demand. 

  

	3.4	Except as set out in Schedule 2, the University will own all equipment purchased or constructed by it, or for it, using the Financial Contribution. 

 

	4.	USE AND EXPLOITATION OF INTELLECTUAL PROPERTY 

  

	4.1	Each Party shall disclose Background Information, Materials & IP owned or controlled by it to the Project that it believes is reasonably required to enable or further the Project. This Agreement does not affect
the ownership of any (i) Background Information, Materials & IP or (ii) technology, design, work, invention, software, data, technique, Know-how, or materials that are not Results and, accordingly, the Parties hereto agree that
all right, title and interest in the Background Information, Materials & IP of each Party will remain the property of each such Party (or its licensors, as applicable). No licence to use any Background Information, Materials & IP
or any other Intellectual Property is granted or implied by this Agreement except the rights expressly granted in this Agreement. 

  
 ***Confidential
Treatment Requested*** 

	4.2	Each Party grants the other a limited, royalty-free, fully paid, non-exclusive licence to use its Background Information, Materials & IP for the purpose of carrying out the Project during the Project Period,
but for no other purpose. Neither Party may grant any sub-licence to use the other’s Background Information, Materials & IP except that the Sponsor may allow its Affiliates and any person or entity working for or on behalf of the
Sponsor or its Affiliates to use the University’s Background Information, Materials & IP for the purpose of carrying out the Project and subject to confidentiality terms at least as restrictive as those set out in section 6 below.

  

	4.3	The University shall not duplicate or reverse engineer the Materials provided by the Sponsor pursuant to the Project or disseminate the Materials to any third party. The University agrees that persons who may have
access to the Material shall be limited to its Principal Investigator and his direct reports. The University shall not use the Material for diagnosing, testing in or treatment of human subjects. The University shall comply with all applicable laws
and regulations applicable to the handling, use and disposal of the Material. Any Material remaining upon completion of the Project shall either be returned to the Sponsor or discarded consistent with Sponsor’s written instructions and
applicable laws and regulations. 

  

	4.4	The Sponsor will own the Intellectual Property in the Results and may take such steps as it may decide from time to time, and at its own expense, to register and maintain any protection for Intellectual Property
included in the Results, including filing and prosecuting patent applications for any of the Inventions included in the Results, in each case without additional compensation or consideration to the University. Where a third party such as a student
or contractor is involved in the Project, the University or the Party engaging that contractor (as the case may be) will ensure that the student and the contractor assign any Intellectual Property they may have in the Results in order to be able to
give effect to the provisions of this clause 4. The University will ensure that its employees and students involved in the creation of the Results give the Sponsor such assistance as the Sponsor may reasonably request in connection with the
registration and protection of the Intellectual Property in the Results, including filing and prosecuting patent applications for any Inventions included in the Results, and taking any action in respect of any alleged or actual infringement of the
resulting Intellectual Property. The University will assign and does hereby irrevocably assign all of its rights, title and interest to the Results to the Sponsor. The University shall cooperate in good faith with Sponsor and shall take all measures
and execute all documents as are necessary to assign all of its right, title and interest to the Sponsor, and perfect title solely in the name of Sponsor, for all of the Intellectual Property pertaining to the Results, and to facilitate the filing,
prosecution, defence and enforcement of all such Intellectual Property by the Sponsor, at Sponsor’s sole cost. 

  

	4.5	The University will notify the Sponsor promptly after identifying any Results that the University believes may constitute Inventions, and will supply the Sponsor with copies of such Results. The University will notify
other Results to the Sponsor in the reports provided under clause 2.4 and the Research Reports 2.6. The University will not file any patent applications relating to the Results and hereby confirms that if it does, it will irrevocably assign and
hereby irrevocably assigns such patent applications to the Sponsor for no additional consideration. 

  
 ***Confidential
Treatment Requested*** 

	4.6	The Sponsor grants the University a royalty-free, non-exclusive licence to use the Results for the purpose of carrying out the Project, and in accordance with Clause 4.7 below, but for no other purpose. The University
may not grant any sub-licence to use the Results. Upon the completion of the Project, the license granted to the University under this clause 4 shall automatically and immediately terminate except as otherwise specifically stated herein.

  

	4.7	Despite the assignment or agreement to assign under clause 4.4, the University, its employees and students will have the irrevocable, royalty-free right to use the Results for the purposes of the University’s own
internal academic teaching and other scholarly uses that are undertaken for the sole purpose of education and academic research. Notwithstanding the foregoing, the rights in this clause are subject to the rules on Academic Publication in clause
5 and confidentiality in clause 6. For clarity, such academic and research purposes shall not extend to the use of the Results in collaboration with any for-profit or commercial third party where such party would be granted any (i) rights
to commercially exploit the Results in any way; nor (ii) access to any of the Sponsor’s Background Information, Materials & IP or the Research Reports. 

 

	4.8	The Sponsor will provide the University with such information as the University may reasonably request from time to time to demonstrate that the Sponsor is exploiting or is taking reasonable steps towards exploiting the
Results. If the Sponsor does not demonstrate that it is exploiting any of the Results or is taking reasonable steps towards exploiting them, then the Sponsor may, in its discretion, elect to abandon any patent applications or issued patent included
in the Intellectual Property arising or derived from any Invention included in the Results (the “Abandoned IP”). Following such abandonment, the University shall have the right, but not the obligation, to commence or continue such
prosecution and to maintain any such patent or patent application under its own control and at its own expense and such patent or patent application shall thereafter be excluded from the definition of Results for purposes of this Agreement. Prior to
any such abandonment, the Sponsor shall give the University at least [***] notice and a reasonable opportunity to take over prosecution of such patent or patent application. The Sponsor agrees to cooperate in such activities including execution of
any documents necessary to enable University to retain ownership and control of such patent or patent application and, if necessary, will assign, and hereby assigns, all of its rights and interest to such Abandoned IP to the University.

  
 ***Confidential
Treatment Requested*** 

	5.	ACADEMIC PUBLICATION 

  

	5.1	Subject to clause 5.2 an employee or student of the University (whether or not involved in the Project) may, provided a Confidentiality Notice under clause 5.2 has not been given: 

 

	 	5.1.1	Discuss work undertaken as part of the Project in University seminars, tutorials and lectures; and 

  

	 	5.1.2	Publish the Results, including any Background Information, Materials & IP of the Sponsor (unless it is the Sponsor’s Confidential Information) in support of the Results. 

 

	5.2	The Sponsor and the University anticipate that a high impact academic Publication will arise following the successful conduct of the Project, and nothing in this Agreement shall prevent or hinder the University from
seeking to publish such a Publication, provided that the procedure in this clause 5.3 is followed. The University will submit to the Sponsor, in writing, a copy of the proposed Publication at least 30 days before the date of the proposed submission
for Publication. The Sponsor may, by giving written notice to the University (“a Confidentiality Notice”): 

  

	 	(a)	require the University to delay the proposed Publication for a maximum of [***] months after receipt of the Confidentiality Notice if, in the Sponsor’s reasonable opinion, that delay is necessary in order to seek
patent or similar protection for any of the Sponsor’s Background Information, Materials & IP or any Results that are to be Published; or 

  

	 	(b)	prevent the Publication of any of the Sponsor’s Background Information, Materials & IP that is Confidential Information. For the avoidance of doubt the University shall not publish the full stereochemical
and chemical structure of any of the Sponsor’s Background Information, Materials & IP without the prior written consent of the Sponsor, provided that the Sponsor will consent to the University disclosing in a Publication sufficient
information about the nature of the Sponsor’s Background Information, Materials & IP and the potential use of the same in the treatment of Muscular Dystrophy as would ordinarily be required of a high quality academic Publication.

 The Sponsor must give that Confidentiality Notice within [***] days after the Sponsor receives a copy of the proposed
Publication. If the University does not receive a Confidentiality Notice within such [***] day period, its employee or student may proceed with the proposed Publication, provided that, whether or not a Confidentiality Notice has been given, any of
the Sponsor’s Background Information, Materials & IP that is Confidential Information may not be published. 
  

	6.	CONFIDENTIALITY 

  

	6.1	Subject to clause 5, neither Party will disclose to any third party, nor use for any purpose except carrying out the Project, any of the other Party’s Confidential Information. 

 

	6.2	Neither Party will be in breach of any obligation to keep any Background Information, Materials & IP, Results or other information confidential or not to disclose it to any third party to the extent that it:

  

	 	6.2.1	was known to the Party making the disclosure before its receipt from the other Party, as demonstrated by written records or other tangible documentation, and is not otherwise subject to an obligation of confidentiality
to the other Party; 

  
 ***Confidential
Treatment Requested*** 

	 	6.2.2	is, as of the date of this Agreement, in the public domain, or subsequently enters the public domain through no fault of the receiving Party 

 

	 	6.2.3	has been obtained by the Party making the disclosure from a third party in lawful possession of such information in circumstances where the Party making the disclosure has no reason to believe that there has been a
breach of an obligation of confidentiality owed to the other Party; 

  

	 	6.2.4	is independently developed by the Party making the disclosure as demonstrated by written or other tangible evidence without reference to or benefit of information disclosed to it by the other Party; 

 

	 	6.2.5	is disclosed pursuant to the requirement of any law or regulation (provided, in the case of a disclosure under the Freedom of Information (Scotland) Act 2002 (“the Act”), none of the exceptions to that Act
applies to the information disclosed) or the order of any court of competent jurisdiction, and the Party required to make that disclosure has informed the other of the requirement and the information required to be disclosed, provided,
however, that: 

  

	 	(a)	in the event that either Party hereto is required by applicable statute or regulation or by judicial or administrative process to disclose any part of the Confidential Information which is disclosed to it hereunder
pursuant to this clause 6.2.5, the receiving Party shall (i) promptly notify the disclosing Party of each such requirement and identify the Confidential Information required to be disclosed by such order, regulation, or law so that the
disclosing Party, at its expense, may seek an appropriate protective order or other remedy and (ii) consult with the disclosing Party on the advisability of taking legally available steps to resist or narrow the scope of such requirement; and

  

	 	(b)	if, in the absence of such a protective order the receiving Party is nonetheless required by mandatory applicable law to disclose any part of the Confidential Information which is disclosed to it hereunder, the
receiving Party may make such required disclosure of Confidential Information without liability under this Agreement, provided that the receiving Party shall furnish only that portion of the Confidential Information which it is legally required
under such order, law or regulation; or 

  

	 	6.2.6	is approved for release in writing by an authorised representative of the other Party. 

  

	6.3	The University will not be in breach of any obligation to keep any of the Sponsor’s Background Information, Materials & IP that is not Confidential Information, or any Results, by Publishing any of the
same if the University has followed the procedure in clause 5.2 and has received no Confidentiality Notice within the period stated in that clause. 

  
 ***Confidential
Treatment Requested*** 

	6.4	The Sponsor will not be in breach of any obligation to keep any of the University’s Background Information, Materials & IP, or other information, confidential or not to disclose them to any third party, by
making them available to any Affiliate, or any person working for or on behalf of the Sponsor or an Affiliate, who needs to know the same in order to exercise the rights granted in this Agreement, provided they are not used except as expressly
permitted by this Agreement and the recipient undertakes to keep that Background Information, Materials & IP confidential. 

  

	6.5	If the University receives a request under the Act to disclose any information that, under this Agreement, is the Sponsor’s Confidential Information, it will notify the Sponsor and will consult with the Sponsor
promptly and before making any disclosure under that Act. The Sponsor will respond to the University within 10 days after receiving the University’s notice. If that notice requests that the Sponsor provide information to assist the University
to determine whether or not an exemption to the Act applies to the information requested under that Act, the Sponsor will use its reasonable efforts to provide such information promptly. 

 

	6.6	Neither the University nor the Sponsor will use the other’s name or logo in any press release or product advertising, or for any other promotional purpose, without first obtaining the other’s written consent,
except that: (i) the University may (a) identify the sums received from the Sponsor in the University’s Annual Report and similar publications; disclose certain information pertaining to the Project for the purposes of assessment of
the quality of the research undertaken, and use in the University’s marketing material; (ii) the Sponsor may disclose the existence of this Agreement to its investors or prospective investors; and (iii) as otherwise required by law or
regulation. 

  

	7.	LIMITATION OF LIABILITY 

  

	7.1	Neither of the parties, except under clause 7.8, makes any representation or gives any warranty to the other that any advice or information given by it or any of its employees or students who work on the Project, or the
content or use of any Results or Background Information, Materials & IP will not constitute or result in any infringement of third-party rights. 

  

	7.2	Except under the limited warranty in clause 7.8 and the indemnity in clause 7.3, and subject to clause 7.6, neither Party accepts any liability or responsibility for any use which may be made by the other Party of any
Results, nor for any reliance which may be placed by that other Party on any Results, nor for advice or information given in connection with any Results. 

  

	7.3	The Sponsor will indemnify the University and the Principal Investigator and his direct reports (the Indemnified Parties), and keep them fully and effectively indemnified, against each and every claim made against any
of the Indemnified Parties as a result of the Sponsor’s use of any of the Results or any materials, works or information received from them pursuant to the terms of this Agreement, provided that the Indemnified Party must: 

 

	 	7.3.1	promptly notify the Sponsor of details of the claim; 

  
 ***Confidential
Treatment Requested*** 

	 	7.3.2	not make any admission in relation to the claim; 

  

	 	7.3.3	allow the Sponsor to have the conduct of the defence or settlement of the claim; and 

  

	 	7.3.4	give the Sponsor all reasonable assistance (at the Sponsor’s expense) in dealing with the claim. 

Notwithstanding the foregoing, the indemnity in this clause will not apply to the extent that the claim arises as a result of the Indemnified
Party’s negligence, its breach of clauses 5 or 6, the deliberate breach of this Agreement or its knowing infringement of any third party’s Intellectual Property. 
  

	7.4	Subject to clause 7.6, and except under the indemnity in clause 7.3, the liability of either Party to the other for any breach of this Agreement, any negligence or arising in any other way out of the subject matter of
this Agreement, the Project and the Results, shall not extend: (i) to any indirect damages or losses; nor (ii) to any loss of profits, loss of bargain, loss of revenue, loss of business, or loss of opportunity, whether direct or indirect,
even if, in any such case, the Party bringing the claim has advised the other of the possibility of those losses. 

  

	7.5	Subject to clause 7.6, and except under the indemnity in clause 7.3, the aggregate liability of each Party to the other for all and any breaches of this Agreement, any negligence or arising in any other way out of the
subject matter of this Agreement, the Project and the Results, will not exceed in total the Financial Contribution. 

  

	7.6	Nothing in this Agreement limits or excludes either Party’s liability for: 

  

	 	7.6.1	death or personal injury; 

  

	 	7.6.2	any fraud or for any sort of liability that, by law, cannot be limited or excluded; or 

  

	 	7.6.3	any loss or damage caused by a deliberate breach of this Agreement or a breach of clauses 4.3, 4.4, 4.5, 4.7, 5 or 6. 

  

	7.7	The express undertakings and warranties given by the parties in this Agreement are in lieu of all other warranties, conditions, terms, undertakings and obligations, whether express or implied by statute, common law,
custom, trade usage, course of dealing or in any other way. All of these are excluded to the fullest extent permitted by law. 

  

	7.8	The University warrants to the Sponsor that, to the best of its knowledge and belief but without having undertaken any searches, in relation to any assignment made under or pursuant to clause 4.4 and 4.5:

  

	 	7.8.1	the University has the right to dispose of the Intellectual Property in the Results and that the University it will, at its own cost, do all that it reasonably can to give the title that it purports to give; and

  
 ***Confidential
Treatment Requested*** 

	 	7.8.1	that the Intellectual Property in the Results is free from all charges and encumbrances and rights of any third party (except those that the University is unaware or could not reasonably be aware of). 

 

	8.	FORCE MAJEURE 

 If the performance by either Party of any of its obligations under this Agreement, except
a payment obligation, is delayed or prevented by circumstances beyond its reasonable control, that Party will not be in breach of this Agreement because of that delay in performance. However, if the delay in performance is more than 6 months, the
other Party may terminate this Agreement with immediate effect by giving written notice to the other Party. 
  

	9.	TERMINATION 

  

	9.1	Either Party may terminate this Agreement with immediate effect by giving notice to the other Party if: 

  

	 	9.1.1	the other Party is in breach of any provision of this Agreement and, if it is capable of remedy, the breach has not been remedied within 60 days after receipt of written notice specifying the breach and requiring its
remedy; or 

  

	 	9.1.2	the other Party shall become bankrupt, or shall file a petition in bankruptcy, or if the business of the Sponsor shall be placed in the hands of a receiver, assignee or trustee for the benefit of creditors, whether by
the voluntary act of the Sponsor or otherwise. 

  

	9.2	Each of the parties will notify the other promptly if at any time any of the Key Personnel appointed by that Party is unable or unwilling to continue to be involved in the Project. Within 2 months after the date of that
notice, the Party who originally appointed that member of the Key Personnel will nominate a successor. The other Party will not unreasonably refuse to accept the nominated successor, but if the successor is not acceptable to the other Party on
reasonable grounds, or if the appointor cannot find a successor, either Party may terminate this Agreement by giving the other not less than 2 months’ notice. 

 

	9.3	Clauses 1, 3, 4, 5, 6, 7, 9.3, 9.4, 9.5 and 10 will survive the expiry of the Project Period or the termination of this Agreement for any reason and will continue indefinitely. 

 

	9.4	On the termination of this Agreement, the Sponsor will pay the University for all work done prior to termination. If the Sponsor has paid any of the Financial Contribution in advance and the whole of that contribution
has not, by the end of the Project Period or the termination of this Agreement, been used by the University for the purposes for which that Financial Contribution was provided, the University will return to the Sponsor the unused portion of that
contribution. 

  

	9.5	 Following the termination of this Agreement by the Sponsor under clause 9.2, if the Financial Contribution includes the costs of employing any
University staff involved in the Project, the Sponsor will continue to reimburse, in accordance with clause 3, the 

  
 ***Confidential
Treatment Requested*** 

	 	
actual direct employment costs of staff who were appointed by the University to work on the Project before the service of the notice, and any other non-cancellable commitments, provided that the
University takes all reasonable steps to minimise those costs. Reimbursement will continue until the effective date of termination of each staff contract or the date on which the Project was to have ended (whichever is the earlier). Those direct
employment costs will include a proportion of any redundancy costs that have been incurred by the University as a direct result of the termination of this Agreement, that proportion to be calculated by dividing the individual’s involvement in
the Project by the duration of his period of employment by the University. 

  

	10.	GENERAL 

  

	10.1	Notices: Any notice to be given under this Agreement must be in writing, may be delivered to the other Party or parties by any of the methods set out in the left hand column below, and will be deemed to be
received on the corresponding day set out in the right hand column: 

  

			
	Method of service	  	Deemed day of receipt
		
	By hand or courier	  	the day of delivery
		
	By pre-paid first class post	  	the third Business Day after posting
		
	By recorded delivery post	  	the second Business Day after posting

 The parties’ respective representatives for the receipt of notices are, until changed by notice
given in accordance with this clause, as follows: 
  

			
	For the University:	  	For the Sponsor:
		
	 Name: Ms Diane Taylor
  

Address: University of Dundee
 Research and Innovation
Services
 11 Perth Road
 Dundee DD1 4HN

Scotland
  

email address:
 [***]
	  	 Name: Chandra Vargeese
  

Address: c/o Wave Life Sciences Pte Ltd
 419 Western Avenue

Boston, MA 02135
 USA

 
  
 email address:

[***]

	  

  

	10.2	Headings: The headings in this Agreement are for ease of reference only; they do not affect its construction or interpretation. 

 

	10.3	 Assignment: Neither Party may assign or transfer this Agreement as a whole, or any of its rights or obligations under it, without first
obtaining the written consent of the other Party and that consent may not be unreasonably withheld or delayed. Notwithstanding the foregoing, provided that it gives reasonable notice to the

  
 ***Confidential
Treatment Requested*** 

	 	
University, the Sponsor may assign this Agreement without the consent of the University (i) to a purchaser, merging, or consolidating corporation, or acquirer of all or substantially all of
its assets or business (or that portion thereof to which this Agreement relates) and/or pursuant to any reorganization of such part or (ii) to an Affiliate of the Sponsor. 

 

	10.4	Illegal/unenforceable provisions: If the whole or any part of any provision of this Agreement is void or unenforceable in any jurisdiction, the other provisions of this Agreement, and the rest of the void or
unenforceable provision, will continue in force in that jurisdiction, and the validity and enforceability of that provision in any other jurisdiction will not be affected. 

 

	10.5	Waiver of rights: If a Party fails to enforce, or delays in enforcing, an obligation of the other Party, or fails to exercise, or delays in exercising, a right under this Agreement, that failure or delay will not
affect its right to enforce that obligation or constitute a waiver of that right. Any waiver of any provision of this Agreement will not, unless expressly stated to the contrary, constitute a waiver of that provision on a future occasion.

  

	10.6	No agency: Nothing in this Agreement creates, implies or evidences any partnership or joint venture between the parties, or the relationship between them of principal and agent. Neither Party has any authority to
make any representation or commitment, or to incur any liability, on behalf of the other. 

  

	10.7	Entire agreement: This Agreement constitutes the entire agreement between the parties relating to its subject matter. Each Party acknowledges that it has not entered into this Agreement on the basis of any
warranty, representation, statement, agreement or undertaking except those expressly set out in this Agreement. Each Party waives any claim for breach of this Agreement, or any right to rescind this Agreement in respect of, any representation which
is not an express provision of this Agreement. However, this clause does not exclude any liability which either Party may have to the other (or any right which either Party may have to rescind this Agreement) in respect of any fraudulent
misrepresentation or fraudulent concealment prior to the execution of this Agreement. 

  

	10.8	Intentionally deleted 

  

	10.9	Amendments: No variation or amendment of this Agreement will be effective unless it is made in writing and signed by each Party’s representative. 

 

	10.10	Third parties: No one except a Party to this Agreement has any right to prevent the amendment of this Agreement or its termination, and no one except a Party to this Agreement may enforce any benefit conferred by
this Agreement, unless this Agreement expressly provides otherwise. 

  

	10.11	Governing law: This Agreement is governed by, and is to be construed in accordance with, Scots law. The Scottish Courts will have exclusive jurisdiction to deal with any dispute which has arisen or may arise out
of or in connection with this Agreement, except that either Party may bring proceedings for an injunction in any jurisdiction. 

  
 ***Confidential
Treatment Requested*** 

	10.12	Escalation: If the parties are unable to reach agreement on any issue concerning this Agreement or the Project within [***] days after one Party has notified the other of that issue, they will refer the matter to
Director of Research Services in the case of the University, and to its Chief Executive Officer in the case of the Sponsor in an attempt to resolve the issue within [***] days after the referral. Either Party may bring proceedings in accordance with
clause 10.11 if the matter has not been resolved within that [***] day period, and either Party may apply to the court for an injunction, whether or not any issue has been escalated under this clause. 

 

			
	SIGNED for and on behalf of the University:	 	SIGNED for and on behalf of the Sponsor:
		
	Name: Graham Cowan	 	Name: Paul B. Bolno, M.D,
		
	Position: Head of Contracts & IP Management Research & Innovation Services	 	Position: President & Chief Executive Officer
		
		 	Signature /s/ Paul B. Bolno
	Signature /s/ Graham Cowan	 	

  

	
	Read and understood by the Principal Investigator
	
	Name: Dr Robyn Hickerson
	
	Signature /s/ Robyn Hickerson
	
	
	Date 28-9-15

  
 ***Confidential
Treatment Requested*** 

 SCHEDULE 1 

The Financial Contribution 
 The Sponsor
shall pay to the University the sum of Two Hundred Thousand Pounds Sterling (£200,000) (“Financial Contribution”) in consideration of the University’s work on the Project, in accordance with the following schedule: 

 

							
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
	 [***]
	  		  	[***]	  	
			
	 Total amount payable
	  	£200,000	  	

 All amounts in this Schedule exclude VAT. 

All payments of the Financial Contribution will be made by bank transfer to the University’s bank account: 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 Tel: [***] 

Fax: [***] 
 Account Name: [***] 

Sort Code: [***] 
 Account No: [***] 

IBAN number: [***] 

  
 ***Confidential
Treatment Requested*** 

 SCHEDULE 2 

The Project 
 [Description
of Project] 
 [***, 9 pages] 

  
 ***Confidential
Treatment Requested*** 

 SCHEDULE 3 

Good Data Management Practices 
  

	1.	Research data must be generated using sound scientific techniques and processes; 

  

	2.	Research data must be accurately recorded in accordance with good scientific practices by the people conducting the research; 

  

	3.	Research data must be analysed appropriately, without bias and in accordance with good scientific practices; 

  

	4.	Research data and the Results must be stored securely and be easily retrievable; 

  

	5.	Data trails must be kept to allow people to demonstrate easily and to reconstruct key decisions made during the conduct of the research, presentations made about the research and conclusions reached in respect of the
research; and 

  

	6.	Each Party must have the right, on not less than [***] days written notice, to visit any other Party to verify that it is complying with the above practices and procedures. 

  
 ***Confidential
Treatment Requested***Exhibit

Exhibit 10.1
EXECUTION VERSION

AMENDMENT NO. 3 TO FIRST AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT

THIS AMENDMENT NO. 3 TO FIRST AMENDED AND RESTATED Receivables Purchase Agreement (this “Amendment”) is entered into as of October 21, 2015, by and among Meredith Funding Corporation, a Delaware corporation (“Seller”), Meredith Corporation, an Iowa corporation (“Meredith”), as initial Servicer (the “Servicer”, together with Seller, the “Seller Parties” and each, a “Seller Party”), JPMorgan Chase Bank, N.A. (in its individual capacity as the sole “Financial Institution” and the “Purchaser”), and JPMorgan Chase Bank, N.A., as agent (together with its successors and assigns hereunder, the “Agent”), with respect to that certain First Amended and Restated Receivables Purchase Agreement among the parties hereto dated as of April 25, 2011 (as amended or modified prior to the date hereof, the “Existing Agreement”, and as amended by this Amendment and as the same may be further amended, supplemented, amended and restated or otherwise modified from time to time, the “RPA”).
W I T N E S S E T H :
WHEREAS, the Seller Parties, the Purchaser and the Agent are parties to the Existing Agreement; 
WHEREAS, Meredith, as guarantor (in such capacity, the “Guarantor”) has provided the Parent Guarantee, dated as of April 25, 2011 (as amended, supplemented or otherwise modified through the date hereof, the “Parent Guarantee”) to the Agent, for the benefit of the Persons named therein in relation to the obligations of the Seller under the Transaction Documents; and
WHEREAS, the parties desire to amend the Existing Agreement as hereinafter set forth, and the Guarantor desires to ratify the Parent Guarantee.
NOW, THEREFORE, in consideration of the premises herein contained, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto hereby agree as follows:
1.    Defined Terms.  Capitalized terms used herein and not otherwise defined shall have their meanings as attributed to such terms in the RPA.
2.    Amendments to Existing Agreement.  The Existing Agreement is hereby amended as follows:
2.1    Section 5.1(p) of the Existing Agreement is hereby amended and restated in its entirety to read as follows:
“(p)    Not a Holding Company or an Investment Company.  Such Seller Party is not a “holding company” or a “subsidiary holding company” of a “holding company” within the meaning of the Public Utility Holding Company Act of 1935, as amended, or any successor statute.  Seller is not a “covered fund” under the Volcker Rule.  Such Seller Party is not an 

“investment company” within the meaning of the Investment Company Act of 1940, as amended, or any successor statute.  In determining that the Seller is not an investment company, the Seller is relying on the exemption from the definition of “investment company” set forth in Section 3(c)(5) of the Investment Company Act of 1940, as amended.”.
2.2    Section 10.2(a) of the Existing Agreement is hereby amended and restated in its entirety to read as follows:
(a)    “(a)    If, as a result of any Change in Law, any Funding Source shall be charged any fee, expense or increased cost (i) that subjects any Funding Source to any charge or withholding on or with respect to any Funding Agreement or a Funding Source’s obligations under a Funding Agreement, or on or with respect to the Receivables, or changes the basis of taxation of payments to any Funding Source of any amounts payable under any Funding Agreement (except for changes in the rate of tax on the overall net income of a Funding Source or taxes excluded by Section 10.1) or (ii) that imposes, modifies or deems applicable any reserve, assessment, insurance charge, special deposit or similar requirement against assets of, deposits with or for the account of a Funding Source, or credit extended by a Funding Source pursuant to a Funding Agreement or (iii) that affects or would affect the amount of capital or liquidity required to be maintained by such Funding Source, and such Funding Source determines that such Change in Law has or would have the effect of reducing the rate of return on capital of such Funding Source (or its parent) as a consequence of such Funding Source’s obligations hereunder or with respect hereto to a level below that which such Funding Source (or its parent) could have achieved but for such Change in Law (taking into consideration its policies with respect to capital adequacy or liquidity requirements) as reasonably determined by such Funding Source (which determination shall be made in good faith (and not on an arbitrary or capricious basis) and consistent with similarly situated customers of the applicable Funding Source under agreements having provisions similar to this Section 10.2(a) after consideration of such factors as such Funding Source then reasonably determines to be relevant) or (iv) that imposes any other condition the result of which is to increase the cost to a Funding Source of performing its obligations under a Funding Agreement, or to reduce the rate of return on a Funding Source’s capital as a consequence of its obligations under a Funding Agreement, or to reduce the amount of any sum received or receivable by a Funding Source under a Funding Agreement or to require any payment calculated by reference to the amount of interests or loans held or interest received by it, then, upon the later of (x) 15 Business Days after demand by the Agent and (y) the next succeeding Settlement Date, Seller shall pay to the Agent, for the benefit of the relevant Funding Source, such amounts charged to such Funding Source or such amounts to otherwise compensate such Funding Source for such increased cost or reduction.” .
2.3    Section 12.1(d) of the Existing Agreement is hereby amended by inserting a new clause (e) at the end thereof to read as follows:
“(e)    Notwithstanding anything to the contrary in this Section 12.1, each party hereto hereby agrees and consents to the pledge, assignment and/or granting of a security interest by any Conduit in or to all of its rights under this Agreement and the other Transaction Documents to a collateral agent or trustee under such Conduit’s commercial paper note program.”.
2.4    The definition of “LIBO Rate” in Exhibit I to the Existing Agreement is hereby amended by inserting the following sentence at the end thereof:

“If the calculation of the LIBO Rate results in a LIBO Rate of less than zero (0), the LIBO Rate shall be deemed to be zero (0) for all purposes in the Transaction Documents.”.
2.5    The definition of “Scheduled Termination Date” in Exhibit I to the Existing Agreement is hereby amended and restated in its entirety to read as follows: 
““Scheduled Termination Date” means October 20, 2017.”.
2.6    Exhibit I to the Existing Agreement is hereby amended by inserting the following definition in its appropriate alphabetical order:
““Volcker Rule” means Section 13 of the U.S. Bank Holding Company Act of 1956, as amended, and the applicable rules and regulations thereunder.”.
3.    Representations and Warranties.  In order to induce the Agent and the Purchaser to enter into this Amendment, each of the Seller Parties and the Guarantor, as applicable, hereby represents and warrants to the Agent and the Purchaser that after giving effect to the amendments contained in Section 2 above, (a) no Termination Event or Potential Termination Event exists and is continuing as of the Effective Date (as defined in Section 5 below), and (b) each of such Seller Party’s or Guarantor’s, as applicable, representations and warranties contained in Section 5.1 of the Existing Agreement and Section 5 of the Parent Guarantee is true and correct as of the Effective Date.
4.    Ratification of Parent Guarantee.  The Guarantor hereby acknowledges and agrees that, immediately after giving effect to this Amendment, the Parent Guarantee shall remain in full force and effect and is hereby ratified and confirmed in all respects.  
5.    Effective Date.  This Amendment shall become effective as of the date first above written (the “Effective Date”) when the Agent has received the following:
		
	(a)
	counterparts of this Amendment, duly executed by the Seller Parties, the Agent and the Purchaser or other evidence satisfactory to the Agent of the execution and delivery of this Amendment by such parties; 

		
	(b)
	counterparts of that certain seventh amended and restated fee letter, dated as of the date hereof (the “A&R Fee Letter”), among the Agent and the Seller, duly executed by each of the parties thereto or other evidence satisfactory to the Agent of the execution and delivery of the A&R Fee Letter by such parties; and

		
	(c)
	payment in full of all applicable fees as specified in the A&R Fee Letter.  

6.    Ratification of Existing Agreement.  The Existing Agreement, as modified hereby, is hereby ratified, approved and confirmed in all respects.
7.    Reference to Agreement.  From and after the Effective Date hereof, each reference in the Existing Agreement to “this Agreement”, “hereof”, or “hereunder” or words of like import, and all references to the Existing Agreement in any and all agreements, instruments, documents, notes, certificates and other writings of every kind and nature shall be deemed to mean the Existing Agreement, as modified by this Amendment.  

8.    Costs and Expenses.  The Seller agrees to pay all costs, fees, and out-of-pocket expenses incurred by the Agent in connection with the preparation, execution and enforcement of this Amendment and the A&R Fee Letter including the reasonable fees of the Agent’s legal counsel, Mayer Brown LLP, within thirty (30) days of presentation of a written invoice therefor.  
9.    CHOICE OF LAW.  THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS (AND NOT THE LAW OF CONFLICTS) OF THE STATE OF ILLINOIS.
10.    Execution in Counterparts.  This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Amendment.
<signature pages follow>

IN WITNESS WHEREOF, the Seller Parties, the Guarantor, the Purchaser and the Agent have executed this Amendment as of the date first above written.

MEREDITH FUNDING CORPORATION, as a Seller Party

By: /s/ Kevin M. Wagner                        
Name: Kevin M. Wagner
Title:     President

MEREDITH Corporation, as a Seller Party and as Guarantor

By: /s/ Steven M. Cappaert                        
Name: Steven M. Cappaert
Title:     Corporate Controller

JPMORGAN CHASE BANK, N.A, as a Financial Institution, Purchaser and as Agent

By: /s/ Richard Barritt                        
Name:     Richard Barritt
Title:      Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]